This will be a single-center, cross-sectional survey based study to be distributed to parent/legal guardians of pediatric patients with Celiac Disease during scheduled Pediatric Gastroenterology clinic visits. Eligible participants will complete a single survey regarding their experiences with accidental gluten exposure in their child, associated symptoms, impact on daily activities, and strategies used to manage symptoms. For pediatric patients over the age of 12 and able, will also recommend their assent and participation in survey completion with their parent/legal guardian. Due to infrequency of visits, the survey may also be distributed via a secondary electronic method such as MyChart or email. The aim of this study will be to show among pediatric patients with Celiac Disease, the majority of patients and parents rely on non–evidence-based interventions rather than consulting with a medical provider for symptom control after accidental gluten exposure.

This study will test the effect of a 6-session occupational therapy program delivered via online video visits called telerehabilitation. The study will involve stroke survivors who have had a stroke at least 1 month ago and have weakness of one arm or hand from the stroke. The occupational therapy sessions will take place while the stroke survivor is located in his/her own home. The stroke survivor will interact with a licensed, experienced occupational therapist via a video call on the stroke survivor's own phone, tablet or laptop. The goal of the telerehabilitation program will be to improve the stroke survivor's abilities to be more engaged in meaningful life activities. The entire study will occur over a 6-week period.

This research study evaluates the effects of an investigational medication, NAC, in individuals with Bipolar Disorder and Alcohol Use Disorder. Participants in the study will be assigned to one of two medication conditions and will take either NAC or a matched placebo. Study medication will be taken for 28 days. There will be 5 study visits, with 3 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.

The goal of this study is to determine which brain health interventions are most beneficial for different people with memory concerns. Participants will complete two at-home interventions that are paired with transcutaneous auricular vagus nerve stimulation (taVNS). The first is computerized brain games, and the other is mindfulness training (MIND). Participants will be randomly assigned to complete one program first and then switch to the other program.

This research study aims to better understand patient experiences with accessing genetic counseling services for hypermobile Ehlers-Danlos syndrome (hEDS). The study will include a review of MUSC medical records to better understand referral patterns to genetic counseling services among patients with hEDS. Patients with hEDS will also be asked to complete a survey about their experiences with accessing genetic counseling services. Healthcare providers will be asked to complete a separate survey about their experiences referring patients with hEDS to genetic counseling services and potential factors that may influence the referral process. The surveys will take approximately 10-15 minutes to complete.

There are minimal risks to participants but may include possible loss of confidentiality or discomfort when answering questions related to healthcare experiences. There is no direct benefit to participants, but the information provided may help improve access to genetic counseling services for future patients with hEDS. Participation in the surveys is completely voluntary.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 2. Administered upon wakening and a second time 3-5 hours later, 3 different doses will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 1. Administered upon wakening and a second time 5-7 hours later, 2 different doses (6mg and 10mg) will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

This study is for patients diagnosed with a solid tumor malignancy of any stage and identified as high risk (having a 6-month mortality estimate). The study is evaluating A-PACT (algorithm-Enables Patients Activated in Cancer Care through Teams). The subjects will be randomized (like flipping a count) to determine if they will receive A-PACT with usual care or usual care alone. The primary purpose of this study is to determine if the A-PACT Program reduces unplanned hospital visits and improves communication between patients and their health care team. Participants in this study can expect to be in this study for 12 months or their withdrawal of consent.

A 95-week study comparing the efficacy and safety of a specific dose of a trial product named zenagamtide versus two different doses of semaglutide, administered once weekly via injection along with a reduced-calorie diet and increased physical activity on weight management in participants with obesity.

This study is for patients who have undergone surgery for non-small cell lung cancer (NSCLC), and your doctors have found that some cancer may still be present in nearby lymph nodes. The study is being done to figure out if adding radiation therapy after surgery can help lower the chance of lung cancer coming back while keeping side effects at a safe level.

The study is being done to find out if this approach is better or worse than the usual approach for your non-small cell lung cancer (NSCLC) after surgery. The usual approach is defined as care most people get for non-small cell lung cancer and is approved by the Food and Drug Administration (FDA).

If you decide to take part in this study, you will either get chemotherapy or immunotherapy or you will get chemotherapy or immunotherapy plus an additional type of radiation therapy called I²-PORT for up to 24 months

After you finish your treatment, your doctor and study team will continue to follow your condition for side effects and cancer recurrence. Follow-up visits will be every 3 months for 2 years and every 6 months for 3 more years, totaling 5 years of follow-up.

There is evidence that I²-PORT radiation therapy is effective in reducing the risk of cancer returning in certain patients with lung cancer. It is not possible to know now if this approach will extend your time without disease compared to the usual approach. This study will help the study doctors learn things that will help people in the future.

If you choose to take part in this study, there is a risk that the I²-PORT radiation therapy may not be as good as the usual approach for your cancer at preventing your cancer from coming back. Some of the most common side effects that the study doctors know about are reddening, tanning, mild pain, hair loss in treated area, and or tiredness. There may be some risks that the study doctors do not yet know about.